Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jiangsu Olive Sensors High-Tech
300507
5
Jing-Jin Electric Technologies
688280
US Stock MarketDetailed Quotes
SVRA Savara
- 2.960
- -0.040-1.33%
Trading May 7 10:15 ET
510.99MMarket Cap-6.17P/E (TTM)
3.030High2.940Low84.93KVolume3.000Open3.000Pre Close252.30KTurnover0.08%Turnover RatioLossP/E (Static)172.63MShares5.11052wk High2.98P/B301.28MFloat Cap2.25552wk Low--Dividend TTM101.78MShs Float9414.996Historical High--Div YieldTTM3.00%Amplitude0.690Historical Low2.970Avg Price1Lot Size
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Savara Stock Forum
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
The debt financing strengthens Savara's balance sheet following its filing of a biologics license application with the US Food and Drug Administration for Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease, the company said.
If the FDA grants priority review, Molbreevi could be approved by the end of the year, Savara s...
Game-Changing Finger-Prick Test Could Transform Rare Lung Disease Diagnosis - What Makes It Special?
Game-Changing Results: This Rare Disease Treatment Just Eliminated Need for Invasive Lung Procedures
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Savara Inc. (SVRA) announced the publication of a manuscript in ERJ Open Research detailing long-term outcomes of molgramostim inhalation solution in treating autoimmune pulmonary alveolar proteinosis (aPAP). The retrospective study evaluated five aPAP patients who received molgramostim thro...
2 MINUTES AGO, 8:39 AM EST
VIA BUSINESSWIRE
-- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease Burden, Restored Patient Functionality, and Reduction of Clinical Symptoms
Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not all bad news crash the pri...
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...
No comment yet